Table 1.
Patient and clinical characteristics of participants at baseline (intrathecal baclofen‐treated group and placebo‐treated control group)
| ITB‐treated group (n=17) | Placebo‐treated group (n=16) | |
|---|---|---|
| Mean age (SD); range (y:mo) | 14:1 (4:1); 9:4–22:8 | 14:7 (4:0); 9:0–20:5 |
| Sex | ||
| Female | 4 (24) | 5 (31) |
| Male | 13 (76) | 11 (69) |
| Mean weight (SD); range (kg) | 35.2 (13.3); 20–75 | 31.9 (9.1); 20–53 |
| Mean height (SD); range (cm) | 148.6 (20.9); 118–181 | 147.8 (19.2); 110–175 |
| GMFCS level | ||
| IV | 8 (47) | 5 (31) |
| V | 9 (53) | 11 (69) |
| MACS level | ||
| III | 2 (12) | 1 (6) |
| IV | 4 (23) | 4 (25) |
| V | 11 (65) | 11 (69) |
| C‐BiLLT (age‐equivalent of comprehension of spoken language) | ||
| <2y | 1 (6) | 3 (19) |
| 2–3y | 1 (6) | 2 (12) |
| >3y | 12 (70) | 10 (63) |
| Missing | 3 (18) | 1 (6) |
Data are n (%) unless otherwise stated. ITB, intrathecal baclofen; GMFCS, Gross Motor Function Classification System; MACS, Manual Ability Classification System; C‐BiLLT, Computer‐Based instrument for Low Motor Language Testing.